Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The case for genomic patenting

G Poste1

  • 1SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406-5939, USA.

Nature
|December 7, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors.

Scientific reports·2025
Same author

Whatever happed to the industry I was told to distrust?

Immunology today·2014
Same author

Chemosensitization of murine fibrosarcoma cells to drugs affected by the multidrug resistance phenotype by the antidepressant trazodone - an experimental-model for the reversal of intrinsic drug-resistance.

International journal of oncology·2011
Same author

Circumvention of multidrug-resistance in murine fibrosarcoma and colon-carcinoma cells by treatment with the alpha-adrenoceptor antagonist furobenzazepine.

International journal of oncology·2011
Same author

Privacy and confidentiality in the age of genetic engineering.

Texas review of law & politics·2005
Same author

Molecular diagnostics: a powerful new component of the healthcare value chain.

Expert review of molecular diagnostics·2002
Same journal

Daily briefing: How cooperation built the world.

Nature·2026
Same journal

Deep-sea oddities and boatloads of other new species - June's best science images.

Nature·2026
Same journal

From cloning to gene-editing: the enduring legacy of Dolly the sheep.

Nature·2026
Same journal

Time to give hydration breaks the red card? What science says about keeping cool.

Nature·2026
Same journal

Universities are relying on AI-detection software to catch cheating. How well do the programs work?

Nature·2026
Same journal

Daily briefing: 'Cyborg' cockroaches breathe underwater with printed suit.

Nature·2026
See all related articles

Opposition to patenting genomic inventions risks undermining intellectual property rights. This could hinder the development of essential medical innovations like new drugs and diagnostic tests.

Area of Science:

  • Biotechnology
  • Intellectual Property Law

Background:

  • Patenting of genomic inventions is crucial for incentivizing research and development.
  • There is growing opposition to the patenting of genetic material and associated technologies.

Purpose of the Study:

  • To analyze the impact of opposition to genomic invention patents on the pharmaceutical and biotechnology industries.
  • To assess the potential consequences for the development pipeline of new drugs, vaccines, and diagnostic tests.

Main Methods:

  • Review of legal and economic literature on intellectual property rights in biotechnology.
  • Analysis of patent opposition trends and their correlation with R&D investment.
  • Case studies of drug and diagnostic test development affected by patent disputes.
Keywords:
Biomedical and Behavioral ResearchGenetics and ReproductionHuman Genome Organization (HUGO)Human Genome ProjectNational Institutes of Health

Related Experiment Videos

Main Results:

  • Opposition to genomic patents creates uncertainty in the investment landscape.
  • Erosion of intellectual property protection may slow down the translation of research into clinical applications.
  • Reduced R&D funding could impact the availability of future medical advancements.

Conclusions:

  • Maintaining robust intellectual property rights for genomic inventions is vital for fostering innovation.
  • Policy decisions regarding patentability must consider the long-term effects on public health and medical progress.
  • Continued dialogue is needed to balance access to genetic information with the need for research incentives.